Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.

Delve into the specifics of inhaled gene therapy, its mechanisms, applications, and future prospects, it's essential to appreciate the foundational principles of gene therapy that paved the way for these advancements.

With ongoing dose escalation and expansion, CRB-701 holds promise as a next-generation treatment for patients battling advanced cancers.

Dive into the progress and challenges in Antibody-Drug Conjugates formulation and delivery for cancer treatment. We emphasize the advancements in targeting precision and efficacy, while discussing key development challenges like target selection, drug potency, and manufacturing complexities in this evolving oncology field.

Millions use inhalers to treat pulmonary conditions in the UK. What is their environmental impact, and how can they be improved for a sustainable future?

Explore the groundbreaking advancements in inhaled drug delivery, a transformative approach that promises enhanced efficacy and patient convenience

The microneedle drug delivery skin patch is made of hydrogel, making it cheap and sustainable to produce.

Serina Therapeutics licences their continuous drug delivery platform to Pfizer, which includes lipid nanoparticle delivery systems.

Advancements in Small Molecule Drug Formulation has witnessed remarkable progress in recent years including nanotechnology and new improved drug delivery systems.

Samsung Biologics will develop and manufacture drugs for Kurma’s portfolio companies, including by providing CMC drug development.

Before joining Amgen, Dr Tukra got his PhD from Purdue University in Industrial and Physical Pharmacy. While at Purdue he also worked at LyoHUB as an advisor and researcher in industrial and academic projects.

The pharmaceutical industry is increasingly looking for approaches to shorten drug development timelines and save on cost, especially virtual biotech companies who rely heavily on key milestone payments. It is therefore imperative that new chemical entities can be quickly manufactured quickly into clinical drug products.